What Patients Need to Know

Most people don’t think twice about taking a prescription medication they’ve been using for month, or even years. If the bottle looks normal, the pills are intact, and the expiration date is still far off, there’s little reason to suspect anything could be wrong.

That’s why a newly announced recall involving a widely prescribed blood pressure medication is drawing attention. Health officials say certain tablets may not perform as intended once they’re taken, raising concerns that some patients may not be receiving the treatment they expect.

The voluntary recall was initiated on June 5, 2026, by Inventia Healthcare Limited, the Mumbai, India-based manufacturer behind the medication. The recall covers 11,460 bottles of chlorthalidone tablets manufactured by Inventia Healthcare and distributed by New Jersey-based Rising Pharma Holdings, according to FDA enforcement records.

The recalled tablets failed dissolution specifications, meaning they may not dissolve properly in the body. When a tablet doesn’t dissolve as intended, the full dose may not be absorbed into the bloodstream, potentially reducing the medication’s effectiveness.

The recall affects 100-tablet and 1,000-tablet bottles with batch numbers RISA24001 and RISB24002, both carrying an expiration date of April 2027. On June 22, 2026, the FDA assigned the recall an official classification under its three-tier risk system.

The FDA’s Class II Chlorthalidone Recall Classification Explained

More than 11,000 bottles of chlorthalidone have been recalled after testing revealed potential issues that may affect the drug’s effectiveness. When the FDA classified the chlorthalidone recall as Class II on June 22, 2026, it was applying a specific regulatory definition that shapes how urgently patients need to act. A Class II recall means the situation is one in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, according to the FDA. In plain terms, a Class II classification sits in the middle of the FDA’s three-tier system: it’s more serious than a Class III recall (which involves minor violations), but below a Class I recall, which is reserved for products that could cause severe injury or death.

For patients taking recalled chlorthalidone 25-mg tablets, the practical concern is reduced drug efficacy rather than acute toxicity. The tablets may simply not work as well – or at all – in some patients, with no dangerous contaminant involved. For anyone managing blood pressure with this medication daily, a reduction in efficacy is not a trivial concern. High blood pressure quietly damages arteries, the heart, and kidneys over time, and consistent medication coverage is how that damage is prevented.

Why Chlorthalidone Is Considered a Front-Line Drug

Chlorthalidone, a diuretic medication, is used to treat high blood pressure and can also reduce swelling related to heart, kidney, or liver disease, according to the Cleveland Clinic. It belongs to a class of drugs called thiazide-like diuretics, meaning it works by prompting the kidneys to flush out excess fluid and sodium. That reduction in total blood volume lowers the pressure blood exerts against artery walls.

This recall is significant because chlorthalidone isn’t a niche medication. It is a widely prescribed treatment for high blood pressure, a condition that affects millions of adults and often requires consistent, long-term medication use. For patients who rely on the drug to help manage their blood pressure, a quality issue that could reduce its effectiveness is more than a manufacturing proble, it could interfere with a treatment plan designed to lower the risk of serious health complications.

Chlorthalidone is prescribed to treat high blood pressure and fluid retention caused by conditions including congestive heart failure, kidney disease, and liver disease. Patients taking it often have multiple cardiovascular risk factors, which means any disruption to consistent dosing carries real clinical weight.

The Scope of the Problem and a Troubling Pattern

The chlorthalidone recall comes roughly a month after another blood pressure medication was recalled for failed dissolution specifications. Amlodipine and Olmesartan Medoxomil tablets were recalled in May and classified as a Class II recall. Dissolution testing is a standard quality control step – a tablet’s ability to break down in simulated stomach fluid is measured before products are released to market. When those tests fail post-market, it typically signals either a problem with raw ingredients, storage conditions, or the manufacturing process itself.

According to the CDC, high blood pressure was a primary or contributing cause of 680,179 deaths in the United States. According to the same CDC data covering August 2021 to August 2023, 49.1% of U.S. adults age 20 and older have hypertension. With nearly half the adult population in this category, the pool of people potentially affected by any blood pressure medication recall is substantial.

How to Check If Your Medication Is Affected

Anyone who takes 25-mg tablets of chlorthalidone should check the label on the bottle to see if it matches the recalled product description. Specifically, look for batch numbers RISA24001 (on 100-tablet bottles) or RISB24002 (on 1,000-tablet bottles), both with an April 2027 expiration date. The tablets were manufactured by Inventia Healthcare, based in Mumbai, India, and distributed by Rising Pharma Holdings in East Brunswick, New Jersey – that manufacturer and distributor information may also appear on your bottle’s label.

If your bottle matches those details, contact your doctor or pharmacist immediately to discuss next steps, and always consult with a medical professional before discontinuing prescription medication. The FDA has not issued specific patient instructions as of the time of this writing, which makes direct contact with a pharmacist especially important – they can confirm whether your specific bottle is affected and arrange a replacement or alternative.

Checking your prescription bottle takes less than a minute, and the batch number is printed on the label. For 1,000-tablet bottles typically found in pharmacy dispensing settings rather than patient homes, the pharmacist’s role is more direct.

Why You Shouldn’t Stop Your Medication Without Guidance

The instinct when a medication is recalled can be to stop taking it immediately. For blood pressure drugs, that instinct can backfire. Suddenly stopping certain medications can cause a sharp increase in blood pressure called rebound hypertension, according to the Mayo Clinic.

Rebound hypertension is exactly what the name suggests: blood pressure that doesn’t just return to its pre-treatment level but overshoots it. While on medication, the body adapts to the drug’s effects. When the medication is abruptly stopped, the body’s regulatory systems can overcompensate, leading to a spike in blood pressure. That spike can trigger serious consequences – the sudden rise can increase the risk of serious cardiovascular events like heart attacks and strokes, and can also cause symptoms like severe headaches, chest pain, and shortness of breath.

For older adults on multiple cardiovascular medications, the risk is particularly pronounced. Stopping blood pressure medication without medical supervision – even for legitimate reasons like a recall – can increase the risk of cardiovascular events and death, especially when the medication has been part of a long-term treatment plan.

The right course of action, in every case, is to call your doctor or pharmacist before making any changes. A pharmacist can issue a replacement prescription or contact your physician directly. Most pharmacies can switch patients to a different manufacturer’s version of the same drug within the same day.

What to Do Now

The chlorthalidone recall covers a specific product: 25-mg tablets in 100-count or 1,000-count bottles, batch numbers RISA24001 and RISB24002, expiration April 2027, manufactured by Inventia Healthcare. Check your bottle against those identifiers today. If your bottle matches, call your pharmacist before your next scheduled dose. Your pharmacist can confirm whether you have an affected lot, arrange a same-manufacturer replacement or a therapeutically equivalent substitute, and loop in your prescribing physician if needed.

If you’re currently taking chlorthalidone for blood pressure management, keep taking it until you hear otherwise from a healthcare provider. The FDA classified this as a moderate-risk Class II recall. A tablet that may dissolve at reduced efficiency poses a slower, more manageable risk than the blood pressure spike that can follow abrupt discontinuation. Your prescriber can monitor your numbers and adjust accordingly – but only if you stay in the conversation.

Recall Overview:

The blood pressure drugs included in this recall are:

Chlorthalidone Tablets, USP, 25 mg (100 count)

NDC: 64980-599-01
Batch: RISA24001
Expiration date: 04/2027

Chlorthalidone Tablets, USP, 25 mg (1,000 count)

NDC: 64980-599-10
Batch: RISB24002
Expiration date: 04/2027

The medication distributed nationwide by Rising Pharma Holdings, Inc., in East Brunswick, New Jersey.

Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.

Trending Products